LC pro active investors interview, page-7

IMO it sounds like they are going to want to license the HERVax and BVaxx about as immediately as the data drops and if MGM would take my bet it would most likely go straight to GSK. I bet deal was lined up in April when AH took the new seat at TCR2 in an “on to the next one mentality as he is head of acquisitions and R&D for GSK. It’s no coincidence and those folks time is too valuable to just sit around as non executive directors with various startups. The Deal has probably been on table contingent of results under an NDA. I would think that we would move those molecules out the door to pay for more CF33/PD1 without another CR. PD1 development going to get expensive and quickly if it’s as potent as we think after initial open label testing.